OncoCyte Corp (OCX) to Release Earnings on Wednesday
OncoCyte Corp (NYSE:OCX) last announced its quarterly earnings results on Monday, August 14th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). On average, analysts expect OncoCyte Corp to post $-0.54 EPS for the current fiscal year and $-0.54 EPS for the next fiscal year.
OncoCyte Corp (OCX) opened at 6.05 on Wednesday. The stock’s 50 day moving average is $6.47 and its 200-day moving average is $6.46. OncoCyte Corp has a 12 month low of $3.60 and a 12 month high of $7.95. The company’s market capitalization is $189.58 million.
An institutional investor recently bought a new position in OncoCyte Corp stock. Northern Trust Corp purchased a new position in OncoCyte Corp (NYSE:OCX) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 40,732 shares of the company’s stock, valued at approximately $211,000. Northern Trust Corp owned 0.14% of OncoCyte Corp at the end of the most recent quarter.
COPYRIGHT VIOLATION WARNING: “OncoCyte Corp (OCX) to Release Earnings on Wednesday” was published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/11/01/oncocyte-corp-ocx-to-release-earnings-on-wednesday.html.
Separately, Zacks Investment Research upgraded shares of OncoCyte Corp from a “sell” rating to a “hold” rating in a research report on Wednesday, July 19th.
OncoCyte Corp Company Profile
OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.
Receive News & Ratings for OncoCyte Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte Corp and related companies with MarketBeat.com's FREE daily email newsletter.